Prescient Therapeutics Limited (AU:PTX) has released an update.
Steven Yatomi-Clarke, the CEO of Prescient Therapeutics Limited, has announced his decision to step down in early 2025 to join Aurora Biosynthetics. Under his leadership, Prescient has grown significantly, advancing its PTX-100 oncology candidate to the verge of a Phase 2 study and developing innovative cell therapy platforms. The company is now seeking a new CEO to maintain its momentum and build on the progress made in cancer therapies.
For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.